Navigation Links
InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
Date:2/20/2009

BRISBANE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release fourth quarter and full-year 2008 financial results on Thursday, February 26, 2009 at 4:00 p.m. Eastern time. A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 86755415. To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 86755415.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY and a research program focused on small molecules for the treatment of pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche, its development partner) in Phase 1b, a second-generation HCV protease inhibitor
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterMune Announces Issuance of U.S. Patent for ITMN-191
2. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
3. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
4. InterMune to Present at J.P. Morgan Healthcare Conference
5. InterMune to Present at Deutsche Bank Biotech Boston Confab
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Release Third Quarter 2008 Financial Results on November 6
8. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
9. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
10. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
11. InterMune to Present at Canaccord Adams Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... and six-month periods ended June 30, 2015. Biorem,s complete second quarter ... ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended ... 2014 , 2015 , 2014 Revenue ... , 4,433 Gross profit , 1,656 , ...
(Date:8/27/2015)... ... 2015 , ... Inc. Magazine released its annual list of the 5,000 fastest-growing ... growth for the three years through 2014. Being named to the Inc. 5000 list ... the country. , “We are thrilled to make the Inc. 5000 list for ...
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... in Personalized Medicine, recently presented new data on the relationship of genetics and ... 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, ...
(Date:8/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, today announced that ... & Company Emerging Growth Conference on September 2 at ... New York Marriott Marquis. A live ... investor relations section of Roka Bioscience,s website at ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3
... Mich., Feb. 5 Energy,Conversion Devices, Inc. (ECD) (Nasdaq: ... United Solar Ovonic LLC and United Solar Ovonic,Corporation, have ... aggregate commitment of up to $55 million, pursuant to ... Agreement, each with,JPMorgan Chase Bank, N.A. The new credit ...
... Feb. 5 GeneGo, Inc., the leading,systems biology ... their,licensing agreement with GeneGo and have added additional ... and clinical studies,with global access to MetaCore, MapEditor ... analysis of biological OMICs data,featuring a comprehensive collection ...
... 5 DiObex, Inc., a privately held,biotechnology company focused ... today that CEO David Cory will deliver a,corporate presentation ... Biotechnology and Medical Device Conference in New York,New York. ... 6 at,10:20 a.m. at the Grand Hyatt Hotel in ...
Cached Biology Technology:Energy Conversion Devices and United Solar Ovonic Enter Into New $55 Million Secured Credit Facility Agreements 2GSK Extends GeneGo License and Adds New Products 2
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
(Date:8/6/2015)... , Aug. 6, 2015  Today, U.S. ... visit Crossmatch ™ to learn firsthand how ... protect data. Crossmatch is a world leader in ... and expertise are helping federal agencies and commercial ... security.   "The vast majority of ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... major infectious disease today. It is estimated that two ... without active symptoms. Nine million new cases of active ... TB is predominantly a lung disease. It is caused ... cells, but it is still not clear how exactly ...
... the flatworm, planaria, offers new clues for understanding ... Institute have discovered how the worm's cells communicate ... scientists have found that gap-junction (microscopic tunnels directly ... This research, led by Dr. Michael Levin, underlies ...
... in ocean-bottom sediments appears in laboratory tests to ... cells, and potentially with less toxicity than current ... November issue of Cancer Cell. , The experimental ... inhibit cancer cells' proteasomes from working effectively. The ...
Cached Biology News:How does Mycobacterium tuberculosis infect the lung? 2New understanding of regeneration gained by Forsyth scientists 2Compound from marine bacteria shows potential as multiple myeloma therapy 2Compound from marine bacteria shows potential as multiple myeloma therapy 3
Peptide-affinity Purified Polyclonal Antibody to Sphingolipid Receptor Edg8/S1P5...
Peptide-affinity Purified Polyclonal Antibody to MAML1 / Mastermind Peptide with sequence VLPTCPMAEFALPR, from N Terminus of the protein sequence according to NP_055572....
DNA sequencing - plasmids or PCR fragments, 3-7 working days service....
LEAF™ Purified anti-human/mouse/rat ICOS...
Biology Products: